1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The non-hodgkin's lymphoma classification project. Blood. 1997; 89:3909–3918.
2. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011; 105:1684–1692.
Article
3. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006; 107:265–276.
Article
4. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23:4117–4126.
Article
5. Ueno S, Yamaguchi M, Kimura M, Odagiri H, Shiraki K, Uemoto S, et al. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs. Int J Oncol. 2005; 27:1241–1246.
Article
6. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403:503–511.
Article
7. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127:2375–2390.
Article
8. Roncati L, Maiorana A. IgA plasmablastic large B-cell lymphoma. Diagnosis. 2017; 4:105–107.
Article
9. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346:1937–1947.
Article
10. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103:275–282.
Article
11. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009; 15:5494–5502.
Article
12. Roncati L, Maiorana A. Ectopic extra-nodal in situ follicular neoplasia (ISFN). J Hematopathol. 2016; 9:151–153.
Article
13. Yamaguchi M, Ohno T, Oka K, Taniguchi M, Ito M, Kita K, et al. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol. 1999; 105:1133–1139.
Article
14. Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev. 2017; 31:37–42.
Article
15. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117:5019–5032.
Article
16. Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, et al. Double-hit B-cell lymphomas. Blood. 2011; 117:2319–2331.
Article
17. Pemmaraju N, Gill J, Gupta S, Krause JR. Triple-hit lymphoma. Proc (Bayl Univ Med Cent). 2014; 27:125–127.
Article
18. Xiao Y, Cai Y, Tang H, Xiao X. De novo CD5-positive primary cardiac diffuse large B-cell lymphoma coexpressing C-myc and BCL2 in an immunocompetent adult. Eur Heart J. 2017; 38:1937.
Article
19. Bacher U, Haferlach T, Alpermann T, Kern W, Schnittger S, Haferlach C. Several lymphoma-specific genetic events in parallel can be found in mature B-cell neoplasms. Genes Chromosomes Cancer. 2011; 50:43–50.
Article
20. Ittel A, Hélias C, Wissler MP, Toussaint E, Miguet L, Chenard MP, et al. Four genetic lymphoma-specific events (MYC, BCL2, BCL6 and CCND1) identified in a high grade B lymphoma case. Blood Cancer J. 2015; 5:e374.
Article